Buf­fett, Di­mon and Be­zos find their mir­a­cle man, charged with fix­ing a bro­ken health­care sys­tem

War­ren Buf­fett, Jamie Di­mon and Jeff Be­zos have found the per­son they think can fix a bro­ken US health­care sys­tem. And they’re go­ing with a Re­nais­sance man.

At­ul Gawande is tak­ing the reins on Ju­ly 9 with a mis­sion to cre­ate a new en­ti­ty un­bound by prof­it goals. And he’s one of the best-known fig­ures in the in­dus­try.

The com­pa­ny — which still doesn’t have a name — will be based in Boston.

Gawande is a sur­geon at Brigham and Women’s Hos­pi­tal, a pro­fes­sor at the Har­vard TH Chan School of Pub­lic Health and Har­vard Med­ical School plus a best­selling au­thor who has penned 4 books. He al­so writes for The New York­er from time to time.

The three ex­ecs from Ama­zon, Berk­shire Hath­away and JP Mor­gan Chase say they know they’re in for a tough chal­lenge, but Gawande has their con­fi­dence.

“We said at the out­set that the de­gree of dif­fi­cul­ty is high and suc­cess is go­ing to re­quire an ex­pert’s knowl­edge, a be­gin­ner’s mind, and a long-term ori­en­ta­tion,” said Be­zos. “At­ul em­bod­ies all three, and we’re start­ing strong as we move for­ward in this chal­leng­ing and worth­while en­deav­or.”

The three busi­ness head­lin­ers have at­tract­ed plen­ty of at­ten­tion with their al­liance on tam­ing health­care costs, and al­so a lot of skep­ti­cism about what they plan to do as well as what they can ac­com­plish. That skep­ti­cism was height­ened by a Wall Street Jour­nal piece out­lin­ing Di­mon’s rapid as­sur­ances to his big health­care clients that he wasn’t set­ting up a ri­val or­ga­ni­za­tion, liken­ing the ven­ture to a group pur­chas­ing or­ga­ni­za­tion.

Pub­licly, though, the three have lament­ed a sys­tem where ram­pant price in­creas­es have left the na­tion with an in­creas­ing­ly heavy fi­nan­cial bur­den, and it’s a dis­cus­sion which bio­phar­ma com­pa­nies have a di­rect in­ter­est in.

We will have to wait and see what Gawande has in mind for trans­form­ing the sys­tem.

Here’s what he had to say to­day:

I’m thrilled to be named CEO of this health­care ini­tia­tive. I have de­vot­ed my pub­lic health ca­reer to build­ing scal­able so­lu­tions for bet­ter health­care de­liv­ery that are sav­ing lives, re­duc­ing suf­fer­ing, and elim­i­nat­ing waste­ful spend­ing both in the US and across the world. Now I have the back­ing of these re­mark­able or­ga­ni­za­tions to pur­sue this mis­sion with even greater im­pact for more than a mil­lion peo­ple, and in do­ing so in­cu­bate bet­ter mod­els of care for all. This work will take time but must be done. The sys­tem is bro­ken, and bet­ter is pos­si­ble.

Im­age: At­ul Gawande Get­ty/Geisinger Health Sys­tem

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.

The issue goes back to March 2019 when the FDA made very clear to Lexicon and its now departed partner Sanofi that it would not approve their application for a potential Type I diabetes drug because it does not appear to be safe.

Digital render of CPI's Medicines Manufacturing Innovation Centre in Glasgow, Scotland (Image: uk-cpi.com)

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

A manufacturing site that has received interest and investments from large pharma companies and the UK government is opening its doors in Scotland.

The manufacturer CPI (Centre for Process Innovation) has opened a new £88 million ($105 million) “Medicines Manufacturing Innovation Center” in Glasgow, Scotland, to accelerate the development of manufacturing tech and solve longstanding challenges in medicine development and manufacturing.

Pro­tect­ing its megablock­buster, Janssen chal­lenges Am­gen's Ste­lara biosim­i­lar ahead of planned 2023 launch

Johnson & Johnson unit Janssen on Wednesday sued Amgen over the company’s proposed biosimilar to its megablockbuster Stelara (ustekinumab), after Amgen said it was ready to launch next May or as soon as the FDA signs off on it.

If Amgen carries through with that plan, Janssen told the Delaware district court that the Thousand Oaks, CA-based company will infringe on at least two Janssen patents.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck sues Johns Hop­kins for li­cens­ing Keytru­da patents in se­cret and in con­flict with re­search col­lab­o­ra­tion

Merck filed a lawsuit against Johns Hopkins University in Maryland federal court on Tuesday, arguing that the storied university obtained illegal patents as part of its research collaboration with the company and related to its blockbuster cancer drug Keytruda (pembrolizumab).

Merck alleges that the Baltimore-based university obtained and licensed Keytruda-related patents in secret while claiming that Keytruda was developed before and independent of a 2013 research collaboration between the two organizations. Hopkins also sought “hundreds of millions of dollars” tied to Keytruda sales because of the patents, Merck contends.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.